Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Brown TA 2nd, Mittendorf EA, Hale DF, Myers JW 3rd, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Brown TA 2nd, et al. Among authors: anastasopoulou ea. Breast Cancer Res Treat. 2020 Jun;181(2):391-401. doi: 10.1007/s10549-020-05638-x. Epub 2020 Apr 22. Breast Cancer Res Treat. 2020. PMID: 32323103 Free PMC article. Clinical Trial.
Immune biomarkers: how well do they serve prognosis in human cancers?
Baxevanis CN, Anastasopoulou EA, Voutsas IF, Papamichail M, Perez SA. Baxevanis CN, et al. Among authors: anastasopoulou ea. Expert Rev Mol Diagn. 2015 Jan;15(1):49-59. doi: 10.1586/14737159.2015.965684. Epub 2014 Oct 27. Expert Rev Mol Diagn. 2015. PMID: 25345403 Review.
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
Anastasopoulou EA, Voutsas IF, Keramitsoglou T, Gouttefangeas C, Kalbacher H, Thanos A, Papamichail M, Perez SA, Baxevanis CN. Anastasopoulou EA, et al. Cancer Immunol Immunother. 2015 Sep;64(9):1123-36. doi: 10.1007/s00262-015-1717-1. Epub 2015 May 31. Cancer Immunol Immunother. 2015. PMID: 26026288 Free PMC article. Clinical Trial.
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE. Mittendorf EA, et al. Among authors: anastasopoulou ea. Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30. Ann Oncol. 2016. PMID: 27029708 Free PMC article. Clinical Trial.
Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.
Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, Janssen N, Arnogiannaki N, Ardavanis A, Pawelec G, Perez SA, Baxevanis CN. Fortis SP, et al. Among authors: anastasopoulou ea. J Immunother Cancer. 2017 Apr 18;5:39. doi: 10.1186/s40425-017-0240-7. eCollection 2017. J Immunother Cancer. 2017. PMID: 28428887 Free PMC article.
20 results